176 related articles for article (PubMed ID: 37378674)
21. Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency.
Sungu N; Kıran MM
Pol J Pathol; 2023; 74(3):161-170. PubMed ID: 37955535
[TBL] [Abstract][Full Text] [Related]
22. Correlation of mismatch repair protein deficiency, PD-L1 and CD8 expression in high-grade urothelial carcinoma of the bladder.
Hodgson A; Vesprini D; Liu SK; Xu B; Downes MR
J Clin Pathol; 2020 Aug; 73(8):519-522. PubMed ID: 31919144
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
[TBL] [Abstract][Full Text] [Related]
24. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
26. Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tracts.
Aird JJ; Steel MJ; Chow C; Ho J; Wolber R; Gilks CB; Hoang LN; Schaeffer DF
Histopathology; 2020 Mar; 76(4):521-530. PubMed ID: 31677289
[TBL] [Abstract][Full Text] [Related]
27. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
Hodges TR; Ott M; Xiu J; Gatalica Z; Swensen J; Zhou S; Huse JT; de Groot J; Li S; Overwijk WW; Spetzler D; Heimberger AB
Neuro Oncol; 2017 Aug; 19(8):1047-1057. PubMed ID: 28371827
[TBL] [Abstract][Full Text] [Related]
28. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
[TBL] [Abstract][Full Text] [Related]
29. Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3.
Wu S; Shi X; Wang J; Wang X; Liu Y; Luo Y; Mao F; Zeng X
Front Immunol; 2021; 12():561793. PubMed ID: 33717059
[TBL] [Abstract][Full Text] [Related]
30. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.
Hongo T; Yamamoto H; Jiromaru R; Yasumatsu R; Kuga R; Nozaki Y; Hashimoto K; Matsuo M; Wakasaki T; Tamae A; Taguchi K; Toh S; Masuda M; Nakagawa T; Oda Y
Mod Pathol; 2021 Nov; 34(11):1966-1978. PubMed ID: 34218257
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of programmed death-ligand 1 protein expression between primary tumors and lymph node metastatic lesions in oral squamous cell carcinoma].
Xia RH; Hu YH; Zhang CY; Xu SM; Li J
Zhonghua Kou Qiang Yi Xue Za Zhi; 2022 Nov; 57(11):1113-1118. PubMed ID: 36379889
[No Abstract] [Full Text] [Related]
33. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy.
Wang HB; Yao H; Li CS; Liang LX; Zhang Y; Chen YX; Fang JY; Xu J
J Dig Dis; 2017 Oct; 18(10):574-581. PubMed ID: 28851046
[TBL] [Abstract][Full Text] [Related]
34. [Predictive markers of immunotherapy in cervical cancer].
Oliushina EM; Zavalishina LE; Andreeva YY; Kuznetsova OA; Moskvina LV; Frank GA
Arkh Patol; 2023; 85(5):5-12. PubMed ID: 37814844
[TBL] [Abstract][Full Text] [Related]
35. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
36. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
Ta RM; Hecht JL; Lin DI
Gynecol Oncol; 2018 Dec; 151(3):401-406. PubMed ID: 30340772
[TBL] [Abstract][Full Text] [Related]
37. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES
Front Immunol; 2020; 11():596825. PubMed ID: 33424844
[TBL] [Abstract][Full Text] [Related]
38. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
Rischin D; Gil-Martin M; González-Martin A; Braña I; Hou JY; Cho D; Falchook GS; Formenti S; Jabbour S; Moore K; Naing A; Papadopoulos KP; Baranda J; Fury W; Feng M; Stankevich E; Li J; Yama-Dang NA; Yoo SY; Lowy I; Mathias M; Fury MG
Gynecol Oncol; 2020 Nov; 159(2):322-328. PubMed ID: 32917410
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of MMR Status and PD-L1 Expression Using Specimens Obtained by EUS-FNB in Patients with Pancreatic Ductal Adenocarcinoma (PDAC).
Constantin A; Iovănescu V; Cazacu IM; Ungureanu BS; Copăescu C; Stroescu C; Bejinariu N; Săftoiu A
Diagnostics (Basel); 2022 Jan; 12(2):. PubMed ID: 35204385
[TBL] [Abstract][Full Text] [Related]
40. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
Manson QF; Schrijver WAME; Ter Hoeve ND; Moelans CB; van Diest PJ
Clin Exp Metastasis; 2019 Feb; 36(1):29-37. PubMed ID: 30547271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
